IP Library Granted Patent US 10,648,017
Granted Patent B2
US 10,648,017 · App. 15/195,901 · Granted May 12, 2020

Methods for RNA analysis

Inventor: Aniela Wochner (Tübingen, DE)
Assignee: CureVac Real Estate GmbH
C12Q1/6806B01D15/163B01D15/325C07H21/02G01N30/88G01N2030/8827
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,648,017
App. No.
15/195,901
Granted
May 12, 2020
Kind
B2
Abstract

The present invention relates to the field of RNA analysis. In particular, the invention concerns the use of a catalytic nucleic acid molecule for the analysis of an RNA molecule. The invention concerns methods for analyzing the 5′ terminal structures of an RNA molecule having a cleavage site for a catalytic nucleic acid molecule. In particular, the invention concerns a method for determining the presence of a cap structure in an RNA molecule having a cleavage site for a catalytic nucleic acid molecule, a method for determining the capping degree of a population of RNA molecules having a cleavage site for a catalytic nucleic acid molecule, a method for determining the orientation of the cap structure in a capped RNA molecule having a cleavage site for a catalytic nucleic acid molecule and a method for determining relative amounts of correctly capped RNA molecules and reverse-capped RNA molecules in a population of RNA molecules, wherein the population comprises correctly capped and/or reverse-capped RNA molecules that have a cleavage site for a catalytic nucleic acid molecule. Moreover, the present invention provides uses of a catalytic nucleic acid molecule.

Claims (20)

1. A method for analyzing the cap structure at the 5′ terminus of an RNA molecule having a cleavage site for a catalytic nucleic acid molecule, the method comprising the steps of:

a) providing an RNA molecule having a cleavage site for a catalytic nucleic acid molecule,

b) denaturing the RNA molecule, annealing the denatured RNA molecule with the catalytic nucleic acid molecule under conditions allowing cleavage of the denatured RNA molecule to produce a 5′ terminal RNA fragment and at least one 3′ RNA fragment, and

c) determining the presence a cap structure at the 5′ terminus of the RNA molecule.

2. The method of claim 1 , further comprising separating the RNA fragments obtained in step b).

3. The method of claim 2 , wherein the RNA fragments are separated by denaturing gel electrophoresis or liquid chromatography.

4. The method of claim 3 , wherein liquid chromatography comprises high performance liquid chromatography, fast protein liquid chromatography, or reverse phase liquid chromatography.

5. The method of claim 1 , wherein the catalytic nucleic acid molecule has a specific cleavage site.

6. The method of claim 1 , wherein the cleavage site for the catalytic nucleic acid molecule is located within 50 nucleotides of the 5′ terminus of the RNA molecule.

7. The method of claim 1 , wherein the catalytic nucleic acid molecule is a ribozyme.

8. The method of claim 7 , wherein the ribozyme is a hammerhead ribozyme, a hairpin ribozyme, or an hepatitis delta virus ribozyme.

9. The method of claim 1 , wherein the RNA molecule is generated by in vitro transcription.

10. The method of claim 9 , wherein the in vitro transcription is carried out in the presence of a cap analog.

11. The method of claim 10 , wherein the cap analog is selected from the group consisting of G[5′]ppp[5′]G, m 7 G[5′]ppp[5′]G, m 3 2,2,7 G[5′]ppp[5′]G, m 2 7,3′-O G[5′]ppp[5′]G (3′-ARCA), m 2 7,2′-O GpppG (2′-ARCA), m 2 7,2′-O GppspG D1 (β-S-ARCA D1) and m 2 7,2′-O GppspG D2 (β-S-ARCA D2).

12. The method of claim 9 , wherein the in vitro transcribed RNA molecule is enzymatically capped.

13. The method of claim 1 , wherein the RNA molecule is an mRNA molecule.

14. The method of claim 1 , wherein the RNA molecule comprises at least one modification.

15. The method of claim 1 , wherein determining comprises comparing a structural feature or a physical parameter of the cap structure with that of a reference RNA fragment.

16. The method of claim 1 , wherein step c) comprises spectroscopic analysis, quantitative mass spectrometry, or sequencing.

17. The method of claim 1 , wherein determining comprises determining the orientation of a cap on the 5′ terminus of the RNA molecule.

Assignments (3)
CHANGE OF NAME Recorded Nov 12, 2022
From: CUREVAC REAL ESTATE GMBH
To: CUREVAC MANUFACTURING GMBH
Reel/Frame 061932/0502 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2020
From: CUREVAC AG
To: CUREVAC REAL ESTATE GMBH
Reel/Frame 051487/0680 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 28, 2016
From: WOCHNER, ANIELA
To: CUREVAC AG
Reel/Frame 039876/0828 →
Priority Claims (1)
WO PCT/EP2013/003947 · Dec 30, 2013 · international
Continuity (2)
Continuation PCTEP2014003482 · Dec 30, 2014
Related Publication 20160304938A1 · Oct 20, 2016
Cited By (17)
US 12,186,387 US 12,201,680 US 12,208,136 US 12,221,605 US 12,227,549 US 12,240,873 US 12,318,444 US 12,337,031 US 12,385,088 US 12,442,005 US 12,460,204 US 12,514,918 US 12,527,856 US 12,528,855 US 12,533,422 US 12,618,060 US 12,649,914